| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC20000 | LR-90 Featured | LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes. LR-90 is also used in the research of diabetic animal model. |
|
| DC20086 | LRE1 Featured | LRE1 is a specific and allosteric inhibitor of soluble adenylyl cyclase. |
|
| DC12514 | LSD1 inhibitor 24 | LSD1 inhibitor 24 is a novel potent, selective lysine-specific demethylase 1 (LSD1) inhibitor with IC50 of 1 nM, induces CD11b expression in THP-1 cells with EC50 of 8 nM. |
|
| DC22396 | LSD1 inhibitor-1 | LSD1 inhibitor-1 is a bisguanidine polyamine analogue that exhibits noncompetitive and specific LSD1 inhibition, with 14.1% remaining LSD1 activity at 10 uM in vitro. |
|
| DC8541 | ORY-1001(Ladademstat) Featured | ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases. |
|
| DC23384 | LSD1-IN-11p | LSD1-IN-11p is a reversible LSD1 inhibitor with IC50/Kd of 79/21 nM. |
|
| DC23379 | LSD1-IN-32 | LSD1-IN-32 is a potent, reversible lysine specific demethylase 1 (LSD1) inhibitor with biochemical IC50 of 83 nM, Kd of 32 nM, cell EC50 of 0.67 uM. |
|
| DC8698 | L-SelenoMethionine | L-SelenoMethionine is a major natural food-form of selenium. |
|
| DC10665 | LSN3154567(Nampt-IN-1) Featured | LSN3154567 is a novel inhibitor of NAMPT with IC50 of 18 nM (NCI-H1155 cell), 49 nM (Calu-6 cell), 333 nM (HCC1937 cell), and 389 nM (MCF-7 cell), respectively. |
|
| DC23503 | LSP1-2111 | LSP1-2111 is a potent, selective, and brain penetrant group III mGluRs agonist with EC50 of 2.2 and 1.7 uM for mGluR4 and mGluR6, respectively. |
|
| DC10155 | LTURM34 | LTURM34 is a specific DNA-PK inhibitor with an IC50 of 0.034 μM. |
|
| DC24031 | LTV-1 | LTV-1 is a highly potent, cell-permeable and reversible LYP (lymphoid tyrosine phosphatase) inhibitor with IC50 of 508 nM. |
|
| DC10987 | LTX-315 | This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. |
|
| DC10988 | LTX-401 Featured | LTX-401 is a promising immunotherapeutic agent and oncolytic amino acid derivative with significant potential to induce immunogenic cell death (ICD) in cancer cells, particularly in melanoma. Its mechanism of action involves the induction of damage-associated molecular patterns (DAMPs), which are critical for activating the immune system against tumors. |
|
| DC7583 | Idalopirdine(Lu-AE-58054) Featured | Lu AE58054 is an in-vitro potency and selectivity, in-vivo binding affinity and effect of the 5-HT(6)R antagonist with a Ki value of 0.83 nM. |
|
| DC7170 | Lucidin (NSC 30546) | Lucidin (NSC 30546) is a natural component of Rubia tinctorum L. lucidin is mutagenic in bacteria and mammalian cells. |
|
| DC22596 | LUF6000 | LUF6000 is a potent, selective, positive allosteric modulator (enhancer) of human A3 adenosine receptor, enhance Emax but without affecting agonist potency. |
|
| DC23647 | LUF7346 Featured | LUF7346 is a novel hERG allosteric modulator that slows IKr deactivation and positively shifting IKr inactivation. |
|
| DC22906 | Lumateperone Featured | Lumateperone (ITI-007) is a potent 5-HT2A antagonist (Ki=0.54 nM), postsynaptic D2 antagonist(Ki=32 nM), and SERT blocker (Ki= 61 nM). |
|
| DC3174 | lurasidone | Lurasidone is a novel psychotropic agent that has been shown in studies of cloned human receptors to be an antagonist at the 5-HT2A receptor. |
|
| DC12117 | Luteolin 7-O-glucuronide (Luteolin 7-glucuronide4) Featured | Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively. |
|
| DC12118 | Luteolin-3-O-beta-D-glucuronide | Luteolin-3-O-beta-D-glucuronide is a luteolin glucosiduronic acid consisting of luteolin having a beta-D-glucosiduronic acid residue attached at the 3'-position. |
|
| DC12120 | Luteolin-7-rutinoside | Luteolin-7-rutinoside has both anti-arthritic and antifungal activities, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection. |
|
| DC11172 | LV-320 | LV-320 (LV320) is a novel potent, cell-active, allosteric inhibitor of the autophagy-related cysteine protease ATG4B with IC50 of 24.5 uM in ATG4B cleavage assays. |
|
| DC23133 | LX-1031 | LX-1031 is a potent, orally active tryptophan 5-hydroxylase (TPH) inhibitor with potency of 10-100 nM, reduces 5-HT synthesis peripherally. |
|
| DC10765 | LX-2761 | LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control. |
|
| DC21251 | LX-2931 | LX-2931 (LX2931) is a potent, selective and orally bioavailable S1P lyase (S1PL) inhibitor. |
|
| DC23136 | LX7101 | LX7101 is a potent, dual LIMK and ROCK inhibitor with IC50 of 4.3/32//69/32/ nM for LIMK2/LIMK1/ROCK1/ROCK2, respectively. |
|
| DC21256 | LY 2318912 | LY 2318912 is a potent, competitive, small molecule inhibitor of anandamide uptake with IC50 of 7.27 nM, shows high affinity against anandamide transporter binding site with Kd o f7.62 nM. |
|
| DC8602 | LY311727 Featured | LY 311727 is a specific group II sPLA2 (phospholipase A2 (PLA2)) inhibitor which has been reported to attenuate VEGF-mediated platelet-activating factor (PAF) synthesis in HUVEC and BAEC cells. |
|
